Patents Assigned to Eli Lilly and Company
-
Patent number: 11993608Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.Type: GrantFiled: March 15, 2023Date of Patent: May 28, 2024Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne Mcmahon
-
Publication number: 20240148694Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 12, 2023Publication date: May 9, 2024Applicant: Eli Lilly and CompanyInventors: Charles Thomas BENSON, Rachel Nicole RICHEY, Hannah YU
-
Patent number: 11976114Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.Type: GrantFiled: October 27, 2022Date of Patent: May 7, 2024Assignee: ELI Lilly and CompanyInventors: Marcio Chedid, Adam S. Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H. Obungu, Sarah Elisabeth Raines, John Randall Sims, II, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye
-
Patent number: 11976136Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.Type: GrantFiled: July 17, 2020Date of Patent: May 7, 2024Assignees: Eli Lilly and Company, The University of North Carolina at Chapel HillInventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
-
Patent number: 11970485Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: GrantFiled: October 19, 2022Date of Patent: April 30, 2024Assignee: ELI LILLY AND COMPANYInventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
-
Patent number: 11964968Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.Type: GrantFiled: February 6, 2023Date of Patent: April 23, 2024Assignee: ELI LILLY AND COMPANYInventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
-
Patent number: 11957882Abstract: A medication delivery device usable with a medication container wherein advancement of a piston within the container expels medication. The device includes a housing and a drive assembly. The drive assembly includes a drive ribbon having distal and proximal edge sections. The drive ribbon has a retracted configuration defining a spiral and an extended configuration defining a helix. The drive ribbon is movable from the retracted configuration to the extended configuration with the movement defining a drive axis and advancing the piston. In some embodiments, the drive ribbon may not rotate as the drive ribbon is advanced while in other embodiments, the ribbon does rotate. Disclosed drive assemblies include manually driven assemblies, spring driven assemblies and motor driven assemblies. The container may be replaceable to allow for reuse of the device. In some embodiments, replaceable cartridges which include both the medication container and the drive ribbon are employed.Type: GrantFiled: November 30, 2018Date of Patent: April 16, 2024Assignee: ELI LILLY AND COMPANYInventors: Jared Alden Judson, Timothy Lee Moulton, Russell Wayne Perkins
-
Patent number: 11951291Abstract: An injection device assembly including a housing, a syringe, a drive mechanism and a status sensing system and a module are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status sensing system includes a light emitter that emits electromagnetic radiation into the housing transverse to the longitudinal axis, a light detector and a controller. The system determines a current status condition from at least three of the following five status conditions: 1) an injection ready state; 2) a needle insertion state; 3) a drug delivered state; 4) a needle guard present state; and 5) a needle retraction state.Type: GrantFiled: April 12, 2019Date of Patent: April 9, 2024Assignee: Eli Lilly and CompanyInventors: Lampros Kourtis, Sean Matthew Pszenny, Oliver Brian Regele
-
Patent number: 11951285Abstract: An injection device assembly including a housing, a syringe, a drive mechanism and one or more sensing systems are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status sensing system may include one or more main PCB(s) disposed in an end portion of the injection device assembly's housing. The system may determine various parameters related to an operational status of the injection device, including the location of the device's components, an amount of medication remaining in the device, a temperature of the medication, and whether or not the device is properly contacting the user's skin before injection. The system may communicate such determined parameters to an external device via a wireless communication link.Type: GrantFiled: May 14, 2021Date of Patent: April 9, 2024Assignee: ELI LILLY AND COMPANYInventors: Joseph Edward Katuin, Adam Nathaniel Wiesler
-
Patent number: 11939381Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: GrantFiled: July 12, 2019Date of Patent: March 26, 2024Assignee: Eli Lilly and CompanyInventors: Stephen J. Demarest, Yiqing Feng, Juqun Shen, Yang Shen, Stephanie Marie Truhlar
-
Patent number: 11925790Abstract: Processes and devices provide parenteral delivery of therapeutic fluids, in particular high-viscosity therapeutic fluids (e.g., protein therapeutics), by a chemical reaction that generates a gas. A device may include a first actuation chamber containing a first reagent, a second reaction chamber containing a second reagent, and a third therapeutic fluid chamber containing the therapeutic fluid. In a loaded configuration, a plunger separates the first chamber from the second chamber. In a delivery configuration, the plunger allows the first reagent from the first chamber to communicate and react with the second reagent from the second chamber. The generated gas acts upon a plunger to deliver the therapeutic fluid from the third chamber.Type: GrantFiled: February 9, 2018Date of Patent: March 12, 2024Assignee: Eli Lilly and CompanyInventors: William Godwin Atterbury, Corrie Jo Bennison, Robert Jonathan Cain, Michael Funk Chiappetta, Jeffrey Leclair Ellis, David Arthur Holley, Mark Lafever, Beverly Ann Piatt, John Paul Tallarico
-
Patent number: 11926634Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.Type: GrantFiled: January 27, 2023Date of Patent: March 12, 2024Assignee: Eli Lilly and CompanyInventors: Alonso Jose Arguelles Delgado, Boris Arnoldovich Czeskis, Mai Khanh Nguyen Hawk, Douglas Patton Kjell, Yu Lu, Nicholas Andrew Magnus, David Michael Remick
-
Patent number: 11926827Abstract: Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.Type: GrantFiled: May 3, 2023Date of Patent: March 12, 2024Assignee: ELI LILLY AND COMPANYInventors: Barbara Calamini, Sarah Katharina Fritschi, Rebecca Ruth Miles, Andrew Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
-
Patent number: 11918623Abstract: A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.Type: GrantFiled: May 10, 2022Date of Patent: March 5, 2024Assignee: Eli Lilly and CompanyInventors: Vincent John Corvari, Christopher Sears Minie, Dinesh Shyamdeo Mishra, Ken Kangyi Qian
-
Patent number: 11919890Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: March 23, 2021Date of Patent: March 5, 2024Assignee: ;Eli Lilly and CompanyInventors: Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
-
Patent number: D1027974Type: GrantFiled: April 26, 2021Date of Patent: May 21, 2024Assignee: ELI LILLY AND COMPANYInventors: Michael Patrick Correy, James Joseph Costigan, V
-
Patent number: D1028004Type: GrantFiled: March 11, 2022Date of Patent: May 21, 2024Assignee: ELI LILLY AND COMPANYInventors: Korey Allen Clements, Christopher Todd Collins, Lela White Feldmeier, K. Shanté Freeman, Jerome Joseph Hodapp, III, Carol Liao, Joshua David Littlejohn
-
Patent number: D1028005Type: GrantFiled: March 11, 2022Date of Patent: May 21, 2024Assignee: ELI LILLY AND COMPANYInventors: Korey Allen Clements, Christopher Todd Collins, Lela White Feldmeier, K. Shanté Freeman, Jerome Joseph Hodapp, III, Carol Liao, Joshua David Littlejohn
-
Patent number: D1028006Type: GrantFiled: March 11, 2022Date of Patent: May 21, 2024Assignee: ELI LILLY AND COMPANYInventors: Korey Allen Clements, Christopher Todd Collins, Lela White Feldmeier, K. Shanté Freeman, Jerome Joseph Hodapp, III, Carol Liao, Joshua David Littlejohn
-
Patent number: D1028007Type: GrantFiled: March 11, 2022Date of Patent: May 21, 2024Assignee: ELI LILLY AND COMPANYInventors: Korey Allen Clements, Christopher Todd Collins, Lela White Feldmeier, K. Shanté Freeman, Jerome Joseph Hodapp, III, Carol Liao, Joshua David Littlejohn